Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 5/20 | 0.41 |
| ▸ | SMO | Q99835 | 2/20 | 0.41 |
| ▸ | NPY2R | P49146 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17844179 | 0.86 | MEN1 (0.47) | — | |
| SCHEMBL17844237 | 0.83 | PTPN1 (0.41) | — | |
| SCHEMBL17844268 | 0.83 | POLB (0.47) | CYP2C19 | |
| SCHEMBL3549420 | 0.81 | MEN1 (0.43) | HSD11B1MGLL | |
| SCHEMBL17844153 | 0.81 | MAPK8 (0.41) | — | |
| SCHEMBL17844211 | 0.79 | L3MBTL1 (0.45) | HSD11B1 | |
| SCHEMBL17844164 | 0.79 | KAT2B (0.38) | — | |
| SCHEMBL17844177 | 0.74 | JAK2 (0.46) | HSD11B1SMO | |
| SCHEMBL1997124 | 0.74 | CYP2C9 (0.46) | CYP2C9CYP2C19HTR2BMAPK14HSD11B1 | |
| SCHEMBL17844131 | 0.72 | DDB1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016100619-A2 | TREATMENT AND DIAGNOSIS OF CANCER | RGENIX, INC. (US) | 2016-06-23 | — | — | WO | disclosed |